Business Context and Reporting Period
OraSure Technologies, Inc. filed a Form 8-K on September 30, 2016, reporting the entry into a material definitive agreement. The company is incorporated in Delaware and headquartered in Bethlehem, Pennsylvania.
Key Financial Metrics and Facility Details
The filing details a new Revolving Credit Facility rather than historical financial performance metrics such as revenue or profit.
- Facility Amount: Initial aggregate amount of up to $10,000,000.
- Letter of Credit Subfacility: Included within the total limit, capped at $2,500,000.
- Expansion Option: Option to increase commitments by up to $5,000,000 prior to the second anniversary, limited to two increases.
- Interest Rate: LIBOR (1, 2, 3, or 6-month) plus 2.50% per annum.
- Fees: Unused line fee of 0.375% per annum; applicable letter of credit participation and fronting fees.
- Maturity: Three years from the closing date.
- Collateral: First priority security interest in accounts receivable, 65% of the equity of Canadian subsidiary DNA Genotek, Inc., cash equivalents, and related assets.
Material Changes and Covenants
The primary material change is the establishment of the new credit facility with Wells Fargo Bank, National Association, as administrative agent. The agreement includes specific financial covenants:
- Borrowing Base: Borrowings are subject to limitations tied to the eligibility of accounts receivable.
- Fixed Charge Coverage Ratio: Under certain circumstances, the company must maintain a minimum ratio of 1.10 to 1.00, measured monthly and over the trailing twelve fiscal months.
- Default Provisions: Events of default allow lenders to terminate commitments and declare obligations immediately due. A default interest rate of 2.00% per annum applies in excess of the standard rate during certain defaults.
Guidance, Outlook, and Risks
The filing does not provide specific revenue guidance, management outlook, or general risk factors beyond the terms of the credit agreement. The primary risk disclosed is the potential acceleration of debt and increased interest costs upon the occurrence of an event of default or failure to meet the fixed charge coverage ratio.
Investor Verification Checklist
- Verify the current utilization of the $10,000,000 revolving facility and any outstanding letters of credit.
- Confirm the company's compliance with the 1.10 to 1.00 fixed charge coverage ratio covenant.
- Assess the eligibility and aging of accounts receivable, as these determine the borrowing base.
- Review the financial health of the Canadian subsidiary, DNA Genotek, Inc., given the 65% equity pledge.
- Monitor for any future announcements regarding the exercise of the $5,000,000 expansion option.